Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     


Delayed Nasdaq  -  04:00:00 2023-05-26 pm EDT
306.90 USD   +1.03%
05/29Titan medical signs license agreement with intuitive surgical
05/26Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
05/26Sector Update: Health Care
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Intuitive Surgical, Inc. : 43 Days Remain Before June 25, 2013, Lead Plaintiff Deadline in Intuitive Surgical, Inc., Securities Lawsuit, Hagens Berman Reminds Investors

05/13/2013 | 09:35am EDT

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, today reminded investors that 43 days remain before the June 25, 2013, lead plaintiff deadline in a securities class-action lawsuit brought against Intuitive Surgical, Inc. (NASDAQ: ISRG) ("ISRG" or "the company"). Those who have more than $300,000 in losses are encouraged to contact Hagens Berman Partner Reed Kathrein to discuss moving for lead plaintiff by emailing ISRG@hbsslaw.com or calling (510) 725-3000.

Investors who purchased ISRG common stock between Oct. 19, 2011, and April 18, 2013, (the "class period") and have suffered significant losses can also reach an attorney by visiting http://www.hb-securities.com/investigations/ISRG.

On April 26, 2013, a lawsuit was filed in the U.S. District Court for the Northern District of California, alleging that ISRG issued a series of false or misleading statements to investors during the class period. The suit alleges that ISRG failed to fully disclose to investors the financial impact of safety problems with its da Vinci Surgical System, including a number of deaths allegedly caused by the system.

On April 30, 2013, Medscape--an online medical resource for healthcare professionals--reported that the Food and Drug Administration has begun to investigate da Vinci following a spike in adverse event reports (AERs) related to the system's use in surgery. According to Medscape, the number of da Vinci AERs filed with the FDA increased by 34 percent between 2011 and 2012.

A number of lawsuits have been filed against the company seeking damages for injuries allegedly caused by da Vinci. ISRG's stock price suffered a significant decline following media coverage of those suits. The filed investor lawsuit claims that ISRG deceived investors regarding the risk of FDA action against the company.

Investors who wish to serve as lead plaintiff in the case must move the court no later than June 25, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357

ę Business Wire 2013
05/29Titan medical signs license agreement with intuitive surgical
05/26Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
05/26Sector Update: Health Care
05/26Titan Medical Signs IP Licensing Agreement With Intuitive Surgical
05/26Titan Medical Says Signed License Agreement with Nasdaq's Intuitive Surgical
05/26Refile-- Titan Medical Brief: Says Signed License Agreement..
05/26Titan Medical Brief: Says Signe License Agreement with Intuitive Sur..
05/24Equity Markets Fall Amid Focus on Debt-Ceiling Talks
05/24Equity Markets Fall on Debt-Ceiling Impasse, Fed Speculation
05/24Sector Update: Health Care Stocks Decline
More news
Analyst Recommendations on INTUITIVE SURGICAL, INC.
More recommendations
Financials (USD)
Sales 2023 7 142 M - -
Net income 2023 1 556 M - -
Net cash 2023 3 250 M - -
P/E ratio 2023 69,8x
Yield 2023 -
Capitalization 108 B 108 B -
EV / Sales 2023 14,6x
EV / Sales 2024 12,6x
Nbr of Employees 12 120
Free-Float 99,5%
Duration : Period :
Intuitive Surgical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTUITIVE SURGICAL, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 306,90 $
Average target price 306,29 $
Spread / Average Target -0,20%
EPS Revisions
Managers and Directors
Gary S. Guthart Chief Executive Officer & Director
David J. Rosa President
Jamie E. Samath Chief Financial Officer & Senior Vice President
Craig H. Barratt Chairman
Myriam J. Curet Chief Medical Officer & Executive Vice President
Sector and Competitors
-40% off: Our subscriptions help you unlock hidden opportunities!